{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:21:29Z","timestamp":1791469289050,"version":"4.3.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Taiwan Ministry of Health and Welfare","award":["MOHW103-TDU-B-211-113-003"],"award-info":[{"award-number":["MOHW103-TDU-B-211-113-003"]}]},{"DOI":"10.13039\/501100001868","name":"National Science Council in Taiwan","doi-asserted-by":"crossref","award":["NSC102-2628-B-075-004-MY3"],"award-info":[{"award-number":["NSC102-2628-B-075-004-MY3"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"crossref","award":["V103B-024"],"award-info":[{"award-number":["V103B-024"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"crossref","award":["V103C-051; V100D-002-3"],"award-info":[{"award-number":["V103C-051; V100D-002-3"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ijcard.2014.11.182","type":"journal-article","created":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T21:29:14Z","timestamp":1417037354000},"page":"246-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":151,"special_numbering":"C","title":["Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal"],"prefix":"10.1016","volume":"180","author":[{"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chern-En","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2014.11.182_bb0005","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1378\/chest.11-2888","article-title":"The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe","volume":"142","author":"Lip","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0010","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.hrthm.2013.03.017","article-title":"Stroke prevention in atrial fibrillation\u2014an Asian stroke perspective","volume":"10","author":"Tse","year":"2013","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0015","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.hrthm.2014.04.021","article-title":"Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong","volume":"11","author":"Siu","year":"2014","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0020","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (section III). Position Paper of the ESC Working Group on Thrombosis \u2014 Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0025","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0030","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0035","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ijcard.2012.10.052","article-title":"Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation","volume":"168","author":"Guo","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0040","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1160\/TH14-03-0228","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel","volume":"111","author":"Husted","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0045","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1253\/circj.CJ-11-0427","article-title":"Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan \u2014 subanalysis of the J-RHYTHM Registry","volume":"75","year":"2011","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0050","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.amjcard.2011.08.046","article-title":"Insights into management of atrial fibrillation in Asia Pacific gained from baseline data from REgistry on cardiac rhythm disORDers (RecordAF-Asia Pacific [AP]) registry","volume":"109","author":"Amerena","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.acvd.2014.01.001","article-title":"Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey","volume":"107","author":"Gamra","year":"2014","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0060","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/CIRCULATIONAHA.113.005451","article-title":"Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry","volume":"129","author":"Oldgren","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0065","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2012.12.019","article-title":"Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry","volume":"165","author":"Steinberg","year":"2013","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0070","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC Member Countries","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0075","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.amjcard.2009.10.012","article-title":"The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation","volume":"105","author":"Le Heuzey","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0080","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0085","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","article-title":"Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial","volume":"45","author":"Wong","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0090","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","article-title":"Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial","volume":"168","author":"Goto","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0095","first-page":"I-484","article-title":"Edoxaban versus warfarin in East-Asian (including Japanese) patients with atrial fibrillationan ENGAGE AF-TIMI 48 sub-analysis","volume":"78","author":"Koretsune","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0100","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/CIRCEP.113.000858","article-title":"Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation","volume":"7","author":"Siu","year":"2014","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0105","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1212\/WNL.0b013e31829bfde3","article-title":"Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review","volume":"81","author":"Tsai","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1179\/1743132813Y.0000000275","article-title":"Warfarin associated intracerebral hemorrhage in Hong Kong Chinese","volume":"36","author":"Teo","year":"2014","journal-title":"Neurol. Res."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0115","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0120","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/eurheartj\/ehs435","article-title":"Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?","volume":"34","author":"Lip","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0130","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jacc.2014.06.1203","article-title":"Using the CHA2DS2-VASc score for refining stroke risk stratification in \u2018low-risk\u2019 Asian patients with atrial fibrillation","volume":"64","author":"Chao","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0140","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0145","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cjca.2012.01.021","article-title":"Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate\/rhythm control","volume":"28","author":"Skanes","year":"2012","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0155","series-title":"Atrial Fibrillation","first-page":"1","article-title":"Center NCG","year":"2014"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0160","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.amjmed.2012.01.033","article-title":"Risk of falls and major bleeds in patients on oral anticoagulation therapy","volume":"125","author":"Donze","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0165","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0170","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/01.STR.0000198839.61112.ee","article-title":"Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial","volume":"37","author":"Sato","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0175","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijcard.2012.09.187","article-title":"Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact?","volume":"168","author":"Guo","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0180","doi-asserted-by":"crossref","first-page":"e000067","DOI":"10.1161\/JAHA.112.000067","article-title":"Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial","volume":"2","author":"Singer","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0185","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FJC.0b013e31821cd888","article-title":"Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation","volume":"58","author":"Chan","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0190","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00002018-200326080-00004","article-title":"Use of herbal medicines by patients receiving warfarin","volume":"26","author":"Wong","year":"2003","journal-title":"Drug Saf."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0195","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0200","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0205","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.thromres.2014.02.024","article-title":"Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan","volume":"133","author":"Chang","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0210","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0215","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH11-10-0718","article-title":"Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice","volume":"107","author":"Huisman","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0220","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1160\/TH12-03-0209","article-title":"Management consensus guidance for the use of rivaroxaban\u2014an oral, direct factor Xa inhibitor","volume":"108","author":"Turpie","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0225","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0230","author":"Administration FaD"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0235","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/eurheartj\/eht499","article-title":"Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes","volume":"35","author":"Azoulay","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0240","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0245","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1378\/chest.13-2976","article-title":"Relationship of the SAME-TT2R2score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation","volume":"146","author":"Lip","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0250","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11739-014-1065-8","article-title":"A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin","volume":"9","author":"Poli","year":"2014","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0255","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.amjmed.2014.05.023","article-title":"SAME-TTR score, time in therapeutic range and outcomes in anticoagulated patients with atrial fibrillation","volume":"127","author":"Gallego","year":"2014","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0260","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11239-013-1048-z","article-title":"Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use\u2014learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials","volume":"38","author":"Amin","year":"2014","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ijcard.2014.11.182_bb0265","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1160\/TH13-05-0424","article-title":"Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation","volume":"111","author":"Lahaye","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0270","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1160\/TH14-01-0063","article-title":"Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation","volume":"111","author":"Lane","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2014.11.182_bb0275","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1160\/TH12-08-0539","article-title":"Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey","volume":"109","author":"Pisters","year":"2013","journal-title":"Thromb. Haemost."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314023638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314023638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T13:47:46Z","timestamp":1589291266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527314023638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":55,"alternative-id":["S0167527314023638"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.11.182","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.11.182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}